| Supplementary Protection Certificate (SPC) Summary | |||||||||||||||
| SPC No. | 2005/001 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date of filing | 21/01/2005 | ||||||||||||||
| Notification of Application Published | 23/02/2005 | ||||||||||||||
| Status | Revoked | ||||||||||||||
| Notification of Grant Published | 24/08/2005 | ||||||||||||||
| Date of Expiry of SPC | 01/04/2019 | ||||||||||||||
| Applicant |
Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway New Jersey 07065 UNITED STATES OF AMERICA |
||||||||||||||
| Patent Number | 0720599 | ||||||||||||||
| Title of Invention | HYDROXY-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | ||||||||||||||
| Date of Expiry of Patent | 13/09/2014 | ||||||||||||||
| Product Type | Medicinal Product | ||||||||||||||
| Product Identity | Ezetimibe, or a pharmaceutically acceptable salt therof, in combination with a cholesterol biosynthesis inhibitor such as simvastatin. | Market Authorisation | Ireland | Germany | |||||||||||
| Authorisation No | 1091/3/3, 1091/3/4, 1091/4/1, 1091/4/2, 1091/4/3, 1091/4/4 | 58874.00.00; 58874.01.00; 58874.02.00; 58874.03.00 | |||||||||||||
| Authorisation Date | 03/12/2004 | 02/04/2004 | |||||||||||||
| Identity of Product Authorised | Ezetimibe in combination with simvastatin | ||||||||||||||
| Market Authorisation | Germany | ||||||||||||||
| Authorisation No | 58878.00.00; 58878.01.00; 58878.02.00; 58878.03.00 | ||||||||||||||
| Authorisation Date | 02/04/2004 | ||||||||||||||
| Identity of Product Authorised | Ezetimibe in combination with simvastatin | ||||||||||||||
| Market Authorisation | Germany | ||||||||||||||
| Authorisation No | 58866.00.00; 58866.01.00; 58866.02.00; 58866.03.00 | ||||||||||||||
| Authorisation Date | 02/04/2004 | ||||||||||||||
| Identity of Product Authorised | Ezetimibe in combination with simvastatin | ||||||||||||||
| Market Authorisation | Germany | ||||||||||||||
| Authorisation No | 58870.00.00; 58870.01.00; 58870.02.00; 58870.03.00 | ||||||||||||||
| Authorisation Date | 02/04/2004 | ||||||||||||||
| Identity of Product Authorised | Ezetimibe in combination with simvastatin | ||||||||||||||
| Address for Service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||||||||||||||
| Renewal Fees |
|
||||||||||||||
| 19/07/2012 | Change of name and address of proprietor from Schering Corporation, A corporation organised and existing under the laws of the State of New Jersey of 2000 Galloping Hill Road, Kenilworth, New Jersey 07030, United States of America to Merck Sharp & Dohme Corp., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States of America recorded on 12/07/12. | ||||||||||||||
| 31/05/2018 | Controller notified on 30 May 2018 of High Court Proceedings, in which infringement proceedings in respect of SPC 2005/001 have been brought by the petitioners, Merck, Sharp and Dohme Corp against Clonmel Healthcare Limited. | ||||||||||||||
| 27/02/2019 | Controller notified on 27 February 2019 that this matter has been listed for hearing before the High Court on 28 May 2019. | ||||||||||||||
| 01/05/2019 | SPC expired on 01/04/2019. | ||||||||||||||
| 03/03/2021 | Supplementary Protection Certificate No. 2005/001 revoked by Order of the High Court dated 29 November 2019. | ||||||||||||||
| 27/04/2022 | CORRECTION: MEMO DATED 03/03/2021 should read: Supplementary Protection Certificate No. 2005/001 revoked by Order of the High Court dated 11 February 2020. | ||||||||||||||
| 05/07/2023 | Controller notified on 10 September 2021 of Supreme Court decision of 4 August 2021 to grant Merck Sharp & Dohme leave to appeal the Court of Appeal Decision. | ||||||||||||||